CompletedPHASE1, PHASE2NCT02736500
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
Studying Neuroendocrine neoplasm of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Principal Investigator
- Giovanni Paganelli, MDIRST IRCCS, Meldola (FC)
- Intervention
- 28 GBq 177Lu-DOTATATE(drug)
- Enrollment
- 39 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2019
Study locations (2)
- Giovanni Paganelli, Meldola, FC, Italy
- Lisa Bodei, Milan, Italy
Collaborators
Istituto Europeo di Oncologia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02736500 on ClinicalTrials.govOther trials for Neuroendocrine neoplasm of pancreas
Additional recruiting or active studies for the same condition.